Wakui, Masatoshi

写真a

Affiliation

School of Medicine, Department of Laboratory Medicine (Shinanomachi)

Position

Associate Professor

External Links
Page Top ▲

Other Affiliation 【 Display / hide 】

  • （兼務所属）慶應義塾大学病院臨床研究推進センター, 再生医療等支援部門, センター員

Page Top ▲

Career 【 Display / hide 】

  • 1989
    -
    1991

    慶應義塾大学医学部研修医（内科）

  • 1991
    -
    1993

    慶應義塾大学医学部助手（専修医）（内科学）

  • 1991
    -
    1993

    横浜市立市民病院内科

  • 1993
    -
    1995

    慶應義塾大学医学部内科学教室血液研究室（専修医）

  • 1995
    -
    1997

    慶應義塾大学助手（医学部内科学）

display all >>

Page Top ▲

Academic Background 【 Display / hide 】

  • 1983.04
    -
    1989.03

    Keio University, School of Medicine, 医学科

    University, Graduated

Page Top ▲

Academic Degrees 【 Display / hide 】

  • 博士（医学）, Keio University, Dissertation, 2006.09

    Genetic dissection of systemic lupus erythematosus pathogenesis : partial functional complementation between Sle1 and Sle3/5 demonstrates requirement for intracellular coexpression for full phenotypic expression of lupus（全身性エリテマトーデスの成因に関する遺伝学的解析 : Sle1とSle3/5の部分的機能補完は、完全なループス表現型発現のために細胞内共発現が要求されることを示す）

Page Top ▲

Licenses and Qualifications 【 Display / hide 】

  • 日本専門医機構基本領域臨床検査専門医, 日本専門医機構による認定, 2023.01

  • 臨床研修指導医, 第16回慶應義塾大学病院臨床研修指導医養成WS受講

  • 医師免許, 1989.05

  • 臨床検査専門医, 日本臨床検査医学会認定, 2017.09

  • 臨床検査管理医, 2017.12

display all >>

Page Top ▲
 

Research Areas 【 Display / hide 】

  • Life Science / Genome biology

  • Life Science / Pathological biochemistry

  • Life Science / Immunology

  • Life Science / Tumor biology

  • Life Science / Tumor diagnostics and therapeutics

display all >>

Page Top ▲
 

Books 【 Display / hide 】

  • 症候編「出血傾向」

    2024

    Scope: 印刷中 Original author： 涌井昌俊

  • 遺伝子検査技術〜遺伝子分析科学認定士テキスト〜改訂第3版

    公益社団法人 日本臨床検査同学院編, 宇宙堂八木書店, 2023.03

    Scope: 血液学

  • 標準臨床検査医学（第5版）

    高木康、山田俊幸編, 医学書院, 2023.02

  • スタンダード検査血液学（第4版）

    日本検査血液学会編, 医歯薬出版株式会社, 2021.04

  • 検査値の読み方・考え方〜専門医からのアドバイス（第3版）

    WAKUI Masatoshi, 総合医学社, 2021

display all >>

Page Top ▲

Papers 【 Display / hide 】

  • Modeling and predicting individual variation in COVID-19 vaccine-elicited antibody response in the general population

    Nakamura N, Kobashi Y, Kim KS, Park H, Shimazu Y, Zhao T, Nishikawa Y, Omata F, Yoshida M, Abe T, Saito Y, Senoo Y, Takita M, Yamamoto C, Kawamura T, Sugiyama A, Nakayama A, Kaneko Y, eong YD, Tatematsu D, Sato Y, Iwanami S, Fujita Y, Wakui M, Aihara K, Kodama T, Shibuya K, Tani Y, Kawashima M, Nonaka S, Akao M, Iwami S*, Tsubokura M*

    PLOS Digit Health 3 ( 5 ) e0000497 2024.05

    Research paper (scientific journal), Joint Work, Accepted

    　View Summary

    As we learned during the COVID-19 pandemic, vaccines are one of the most important tools in infectious disease control. To date, an unprecedentedly large volume of high-quality data on COVID-19 vaccinations have been accumulated. For preparedness in future pandemics beyond COVID-19, these valuable datasets should be analyzed to best shape an effective vaccination strategy. We are collecting longitudinal data from a community-based cohort in Fukushima, Japan, that consists of 2,407 individuals who underwent serum sampling two or three times after a two-dose vaccination with either BNT162b2 or mRNA-1273. Using the individually reconstructed time courses of the vaccine-elicited antibody response based on mathematical modeling, we first identified basic demographic and health information that contributed to the main features of the antibody dynamics, i.e., the peak, the duration, and the area under the curve. We showed that these three features of antibody dynamics were partially explained by underlying medical conditions, adverse reactions to vaccinations, and medications, consistent with the findings of previous studies. We then applied to these factors a recently proposed computational method to optimally fit an “antibody score”, which resulted in an integer-based score that can be used as a basis for identifying individuals with higher or lower antibody titers from basic demographic and health information. The score can be easily calculated by individuals themselves or by medical practitioners. Although the sensitivity of this score is currently not very high, in the future, as more data become available, it has the potential to identify vulnerable populations and encourage them to get booster vaccinations. Our mathematical model can be extended to any kind of vaccination and therefore can form a basis for policy decisions regarding the distribution of booster vaccines to strengthen immunity in future pandemics.

  • Diminished neutralizing activity against the XBB1.5 strain in 55.9% of individuals post 6 months COVID-19 mRNA booster vaccination: Insights from a pseudovirus assay on 1,353 participants in the Fukushima Vaccination Community Survey, Japan

    Zhao T, Tani Y, Makino-Okamura C, Takita M, Yamamoto C, Kawahara E, Abe T, Sugiura S, Yoshimura H, Uchiyama T, Yamazaki I, Ishigame H, Wakui M, Fukuyama H, Tsubokura M

    Front Immunol (Frontiers in Immunology)  15   1337520 2024.03

    Research paper (scientific journal), Joint Work, Accepted

    　View Summary

    This study investigates the neutralizing activity against the XBB1.5 variant and the ancestral strain in a population post-bivalent vaccination using a pseudo virus assay validated with authentic virus assay. While bivalent booster vaccination and past infections enhanced neutralization against the XBB 1.5 strain, individuals with comorbidities showed reduced responses. The study suggests the need for continuous vaccine updates to address emerging SARS-CoV-2 variants and highlights the importance of monitoring real-world immune responses.

  • 特集：血栓・塞栓症の臨床　血液検査

    涌井昌俊

    日本臨床 (日本臨床社)  82 ( 2 ) 148 - 154 2024.02

    Research paper (scientific journal), Single Work, Lead author, Corresponding author

  • ホットトピックス：凝固（出血）分野

    涌井昌俊、長江千愛、武山雅博

    血栓止血誌 35 ( 1 ) 印刷中 2024

    Research paper (scientific journal), Lead author, Corresponding author

  • PRMT1 methylates PHGDH to sustain de novo fatty acid synthesis for the acquisition of chemoresistance in triple-negative breast cancer cells

    Yamamoto T *, Hayashida T#, Masugi Y, Oshikawa K, Hayakawa N, Itoh M, Nishime C, Suzuki M, Nagayama A, Kawai Y, Hishiki T, Matsuura T, Naito Y, Kubo A, Yamamoto A, Yoshioka Y, Kurahori T, Nagasaka M, Takizawa M, Takano N, Kawakami K, Sakamoto M, Wakui M, Yamamoto T, Kitagawa Y, Kabe Y, Horisawa K, Suzuki A, Matsumoto M, Suematsu M *

    Cancer Res (Cancer Research)  84 ( 7 ) 1065 - 1083 2024

    Research paper (scientific journal), Joint Work, Accepted,  ISSN  00085472

    　View Summary

    Triple-negative breast cancer (TNBC) chemoresistance hampers the ability to effectively treat patients. Identification of mechanisms driving chemoresistance can lead to strategies to improve treatment. Here, we revealed that protein arginine methyltransferase-1 (PRMT1) simultaneously methylates D-3-phosphoglycerate dehydrogenase (PHGDH), a critical enzyme in serine synthesis, and the glycolytic enzymes PFKFB3 and PKM2 in TNBC cells. 13C metabolic flux analyses showed that PRMT1-dependent methylation of these three enzymes diverts glucose toward intermediates in the serine-synthesizing and serine/glycine cleavage pathways, thereby accelerating the production of methyl donors in TNBC cells. Mechanistically, PRMT1-dependent methylation of PHGDH at R54 or R20 activated its enzymatic activity by stabilizing 3-phos-phoglycerate binding and suppressing polyubiquitination. PRMT1-mediated PHGDH methylation drove chemoresistance independently of glutathione synthesis. Rather, activation of the serine synthesis pathway supplied a-ketoglutarate and citrate to increase palmitate levels through activation of fatty acid synthase (FASN). Increased palmitate induced protein S-palmitoylation of PHGDH and FASN to further enhance fatty acid synthesis in a PRMT1-dependent manner. Loss of PRMT1 or pharmacologic inhibition of FASN or protein S-palmitoyltransferase reversed chemoresistance in TNBC. Furthermore, IHC coupled with imaging MS in clinical TNBC specimens substantiated that PRMT1-mediated methylation of PHGDH, PFKFB3, and PKM2 correlates with chemoresistance and that metabolites required for methylation and fatty acid synthesis are enriched in TNBC. Together, these results suggest that enhanced de novo fatty acid synthesis mediated by coordinated protein arginine methylation and protein S-palmitoylation is a therapeutic target for overcoming chemoresistance in TNBC. Significance: PRMT1 promotes chemoresistance in TNBC by methylating metabolic enzymes PFKFB3, PKM2, and PHGDH to augment de novo fatty acid synthesis, indicating that targeting this axis is a potential treatment strategy.

display all >>

Page Top ▲

Papers, etc., Registered in KOARA 【 Display / hide 】

display all >>

Page Top ▲

Reviews, Commentaries, etc. 【 Display / hide 】

  • Editorial

    涌井昌俊

    血栓止血誌 34 ( 1 ) 3 - 3 2023.02

    Rapid communication, short report, research note, etc. (scientific journal), Single Work, Lead author, Corresponding author

  • ジャーナルクラブ：Platelets mediate inflammatory monocyte activation by SARS-CoV-2 spike protein（SARS-CoV-2スパイクタンパクによって血小板は炎症性単球の活性化をもたらす）

    涌井昌俊

    血栓止血誌 34 ( 3 ) 399 - 402 2023

    Article, review, commentary, editorial, etc. (scientific journal), Joint Work

  • ジャーナルクラブ：Platelets enhance CD4+ central memory T cell responses via platelet factor 4-dependent mitochondrial biogenesis and cell proliferation（血小板は血小板第4因子に依存するミトコンドリア生合成と細胞増殖を介してCD4+ セントラルメモリーT細胞応答を増強する）

    涌井昌俊

    (血栓止血誌)  33 ( 6 ) 736 - 739 2022.12

    Rapid communication, short report, research note, etc. (scientific journal), Single Work

    　View Summary

    論文紹介

  • ACB論文紹介5：種々の定量的抗体検査を用いたCOVID-19の液性免疫応答の解析

    涌井昌俊

    臨床化学 51 ( 3 ) 261 - 261 2022.07

    Rapid communication, short report, research note, etc. (scientific journal), Single Work

    　View Summary

    論文紹介

  • 出血性素因

    涌井 昌俊

    臨床検査 (医学書院)  印刷中 2019

    Article, review, commentary, editorial, etc. (trade magazine, newspaper, online media), Single Work

display all >>

Page Top ▲

Presentations 【 Display / hide 】

  • COVID-19ワクチン被接種者における免疫獲得に関する解析

    涌井昌俊

    第104回慶應医学会総会シンポジウム「mRNAワクチン」 (東京) , 

    2024.11
    , 

    Symposium, workshop panel (nominated), 慶應医学会

  • LC-MS/MSによる17-ケトステロイド分画（17-KS分画）測定法の開発

    中川央充、本間桂子、下門聖子、酒井昭子、大野明美、横田浩充、涌井昌俊、松下弘道

    第71回日本臨床検査医学会学術集会 (大阪) , 

    2024.11
    -
    2024.12
    , 

    Oral presentation (general), 日本臨床検査医学会

  • PML::RARAを伴う治療関連骨髄性腫瘍の１例.

    藏藤由樹子、谷田部陽子、荒木美香、荒井智子、横田浩充1、三ツ橋雄之、涌井昌俊、松下弘道

    第71回日本臨床検査医学会学術集会 (大阪) , 

    2024.11
    -
    2024.12
    , 

    Oral presentation (general), 日本臨床検査医学会

  • 血液凝固因子の欠乏によるAPTT-CWA凝固波形異常出現に関する検討.

    藤森祐多、岡周作、涌井昌俊、五十嵐好、尾﨑裕子、近藤佳乃、中村祥子、中川央充、長田恵美里、横田浩充、松下弘道

    第71回日本臨床検査医学会学術集会 (大阪) , 

    2024.11
    -
    2024.12
    , 

    Oral presentation (general), 日本臨床検査医学会

  • 新規血小板内RNA検出法を用いた血小板測定の臨床的有用性

    佐藤廣幸、森文香、荒木美香、谷田部陽子、竹田知広、永井豊、荒井智子、横田浩充、三ツ橋雄之、涌井昌俊、松下弘道

    第71回日本臨床検査医学会学術集会 (大阪) , 

    2024.11
    -
    2024.12
    , 

    Oral presentation (general), 日本臨床検査医学会

display all >>

Page Top ▲

Research Projects of Competitive Funds, etc. 【 Display / hide 】

  • 凝固波形解析の自動診断化：血液凝固異常診療のデジタルトランスフォーメーション

    2023.04
    -
    2026.03

    独立行政法人日本学術振興会, 科学研究費助成事業（学術研究助成基金助成金）, 基盤研究（C）, Research grant, Principal investigator

  • 尿中非抱合型ステロイドによる21水酸化酵素欠損症鑑別法の確立

    2023
    -
    Present

    一般社団法人日本臨床検査医学会, 学術推進プロジェクト研究助成, Other, Coinvestigator(s)

  • 人工知能を用いた凝固検査における直接阻害型経口抗凝固薬血中濃度の指標の探索

    2022.04
    -
    2025.03

    独立行政法人日本学術振興会, 科学研究費補助金, 基盤研究（C）, Research grant, Coinvestigator(s)

  • COVID-19重症化を特徴付ける早期免疫代謝の解明と予後マーカーの探索

    2022.04
    -
    2025.03

    独立行政法人日本学術振興会, 科学研究費補助金, 基盤研究（B）, Research grant, Coinvestigator(s)

  • 日本の医療従事者におけるCOVID-19ワクチンの液性・細胞性免疫応答と副反応の研究

    2021
    -
    Present

    公益財団法人予防接種リサーチセンター, 公益財団法人予防接種リサーチセンター研究費事業, No Setting, Coinvestigator(s)

display all >>

Page Top ▲

Intellectual Property Rights, etc. 【 Display / hide 】

  • 凝固波形を用いた血液凝固異常の推定方法

    Date applied： 特願2023-028516  2023.02 

    Patent, Joint

  • 質量分析データ処理方法及び装置（分割出願）

    Date applied： 特願2016-074892  2016.04 

    Date announced： 特開2016-153798  2016.08 

    Date issued： 特許第6207036号  2017.09

    Patent, Joint

  • MASS-ANALYSYS DATA PROCESSING METHOD AND SYSTEM

    Date applied： US. Patent Application NO.13/458,850  2012.04 

    Date announced： US. Patent Application Publication NO.US2012/0278037 A1  2012.11 

    Date issued： 特許番号10012572  2018.07

    Patent, Joint

  • 質量分析データ処理方法及び装置

    Date applied： 特願2012-102636  2012.04 

    Date announced： 特開2012-237753  2012.12 

    Date issued： 特許第6025141号  2016.10

    Patent, Joint

  • 免疫応答修飾活性の試験管内評価方法

    Date applied： JP2005019149  2005.10 

    Date announced： WO2006-054415  2006.05 

    Date issued： 4886521  2011.12

    Patent, Joint

display all >>

Page Top ▲

Other 【 Display / hide 】

  • 　View Details

    Abstract Reviewer in ISTH2025

  • Abstract Reviewer

    　View Details

    Abstract Reviewer in ISTH 2024

  • peer-review

    　View Details

    peer-review (International Journal of Hematology)

  • peer-review

    　View Details

    peer-review (Circulation)

  • peer-review

    　View Details

    論文査読（日本臨床検査医学会誌（旧・臨床病理））

display all >>

Page Top ▲
 

Courses Taught 【 Display / hide 】

  • PATHOPHYSIOLOGICAL ISSUES IN ACUTE CARE

    2024

  • LECTURE SERIES, LABORATORY MEDICINE

    2024

  • ADVANCED MEDICAL TECHNOLOGIES

    2024

  • PATHOPHYSIOLOGICAL ISSUES IN ACUTE CARE

    2023

  • LECTURE SERIES, LABORATORY MEDICINE

    2023

display all >>

Page Top ▲

Courses Previously Taught 【 Display / hide 】

  • 臨床検査学

    Keio University

    2018.04
    -
    2019.03
    , 

    Spring Semester, Lecture, Within own ｆaculty

  • 臨床検査学

    Keio University

    2018.04
    -
    2019.03
    , 

    Full academic year, Laboratory work/practical work/exercise

  • 臨床検査学

    Keio University

    2018.04
    -
    2019.03
    , 

    Autumn Semester, Seminar

  • 実験動物医学

    Keio University

    2018.04
    -
    2019.03
    , 

    Spring Semester, Lecture

  • 基礎腫瘍学

    Keio University

    2018.04
    -
    2019.03
    , 

    Spring Semester, Lecture

display all >>

Page Top ▲

Educational Activities and Special Notes 【 Display / hide 】

  • OSCE内部評価者

    2020
    -
    Present

    , Special Affairs

  • 医療系三学部合同教育

    2018
    -
    Present

    , Special Affairs

  • 病院での臨床検査. 第1版, 東京：慶應義塾大学薬学部

    2013

    , Development of Textbook and Teaching Material

  • 医学部カリキュラム委員会

    2010
    -
    2014

    , Special Affairs

  • 医学部入試試験監督

    2010

    , Special Affairs

display all >>

Page Top ▲
 

Social Activities 【 Display / hide 】

  • 季刊学術情報誌「Vita」編集委員

    BML, 季刊学術情報誌「Vita」, 

    , 
    2023.09
    -
    Present

  • 日本臨床検査専門学院第46期（令和3年度）血液学コースカリキュラム

    一般社団法人　日本衛生検査所協会

    2021
    -
    Present

  • 『臨床検査』誌編集委員

    医学書院

    2019.11
    -
    Present

  • 2019年度慶應連合三田会大会実行委員（救護部会）

    2019年度慶應連合三田会大会実行委員会, 2019年度慶應連合三田会大会 (慶應義塾大学　日吉キャンパス)

    , 
    2019.10

  • 『臨床検査』誌ゲストエディター

    医学書院, 臨床検査, 

    , 
    2019
    -
    Present

display all >>

Page Top ▲

Media Coverage 【 Display / hide 】

  • APAC Customer Focus Group Session

    Roche Diagnostics International Ltd,  (Online) , 2021.07

Page Top ▲

Memberships in Academic Societies 【 Display / hide 】

  • 日本臨床化学会, 

    2019.01
    -
    Present

  • 日本臨床検査専門医会, 

    2018.01
    -
    Present

  • 日本医用マススペクトル学会, 

    2018
    -
    Present

  • International Society of Laboratory Hematology, 

    2016
    -
    Present

  • 慶應医学会, 

    1989
    -
    Present

display all >>

Page Top ▲

Committee Experiences 【 Display / hide 】

  • 2024.11

    第104回慶應医学会総会シンポジウム（東京）　座長, 慶應医学会

  • 2024.11

    第71回日本臨床検査医学会学術集会（大阪）　一般演題（口演）座長, 日本臨床検査医学会

  • 2024.10
    -
    2025.09

    日本医用マススペクトル学会2025年度奨励賞選考委員, 日本医用マススペクトル学会

  • 2024.09

    第49回医用マススペクトル学会年会（京都）ランチョンセミナー座長, 医用マススペクトル学会

  • 2024.08

    第64回日本臨床化学会年次学術集会（宇都宮）　一般演題（口演）座長, 日本臨床化学会

display all >>

Page Top ▲